A practical reference on cyclic heptapeptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-08-07 and is reviewed periodically as new material appears.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Alpha-MSH analogue with a lactam ring |
| Molecular formula | C50H69N15O9 | Commonly cited value for the neutral peptide |
| Molecular weight | 1024.18 g/mol | Calculated for the free molecule |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water, DMSO and ethanol | Dissolution in pure water is often slow |
ARGX-115 is a first-in-class immunotherapy targeting GARP (glycoprotein A repetitions predominant), a membrane protein believed to enhance the immunosuppressive effects of T cells. The company also announced a deal to co-develop/commercialize at least one of CytomX Probody's conjugates against CD71 (transferrin receptor 1). In June 2019, AbbVie announced it would acquire Irish-based Allergan plc for about $63 billion; however the transaction was not structured as a tax inversion; AbbVie remained legally domiciled in the U.S. for tax purposes. To gain FTC approval, the company divested Allergan's late-stage gastrointestinal candidate brazikumab to AstraZeneca as well as two pancreatic replacement enzymes, Zenpep and Viokace, to Nestlé. In July 2019, the company announced it would acquire Mavupharma, boosting its cancer drug pipeline. In March 2020, during the COVID-19 pandemic, AbbVie announced plans to evaluate the Kaletra/Aluvia HIV medicine as possible COVID-19 treatment. The company entered into various partnerships with health authorities in different countries to investigate the efficacy of the medication. However, the first non-blinded, randomized trial found the drug not useful to treat severe COVID-19. The Israeli government announced that it would force AbbVie to license its patents for Kaletra, the brand name of lopinavir/ritonavir, a fixed dose combination medication for the treatment and prevention of HIV/AIDS which was also thought to have some applicability to fighting COVID-19.
lethal mutation Any mutation that results in the premature death of the organism carrying it. Recessive lethal mutations are fatal only to homozygotes, whereas dominant lethals are fatal even in heterozygotes.
== External links == XB1: The First Conference on Xenobiology Archived 2019-04-03 at the Wayback Machine May 6–8, 2014. Genoa, Italy. XB2: The Second Conference on Xenobiology May 24–26, 2016. Berlin, Germany.
=== Antibody heterogeneity === Product heterogeneity is common in monoclonal antibodies and other recombinant biological products and is typically introduced either upstream during expression or downstream during manufacturing. These variants are typically aggregates, deamidation products, glycosylation variants, oxidized amino acid side chains, as well as amino and carboxyl terminal amino acid additions. These seemingly minute structural changes can affect preclinical stability and process optimization as well as therapeutic product potency, bioavailability and immunogenicity. The generally accepted purification method of process streams for monoclonal antibodies includes capture of the product target with protein A, elution, acidification to inactivate potential mammalian viruses, followed by ion chromatography, first with anion beads and then with cation beads. Displacement chromatography has been used to identify and characterize these often unseen variants in quantities that are suitable for subsequent preclinical evaluation regimens such as animal pharmacokinetic studies. Knowledge gained during the preclinical development phase is critical for enhanced product quality understanding and provides a basis for risk management and increased regulatory flexibility. The recent Food and Drug Administration's Quality by Design initiative attempts to provide guidance on development and to facilitate design of products and processes that maximizes efficacy and safety profile while enhancing product manufacturability.
Sources: en.wikipedia.org
=== Population === Hyperglycemia is one of the main symptoms of diabetes and it has substantially affected the population making it an epidemic due to the population's increased calorie consumption. Healthcare providers are trying to work more closely with people allowing them more freedom with interventions that suit their lifestyle. As physical inactivity and calorie consumption increases it makes individuals more susceptible to developing hyperglycemia. Hyperglycemia is caused by type 1 diabetes and non-whites have a higher susceptibility for it.
A large number of illnesses and diseases are caused by mutations in alleles of the genes that regulate the production of actin or of its associated proteins. The production of actin is also key to the process of infection by some pathogenic microorganisms. Mutations in the different genes that regulate actin production in humans can cause muscular diseases, variations in the size and function of the heart, as well as deafness. The make-up of the cytoskeleton is also related to the pathogenicity of intracellular bacteria and viruses, particularly in the processes related to evading the actions of the immune system.
=== Physical stability === Micromeritic properties of a particle, i.e. the particle size in a formulation, influence the physical stability of the suspensions and emulsions. The smaller the size of the particle, the better the physical stability of the dosage form owing to the Brownian motion of the particles in the dispersion.
== Pseudomonas syringae as a model system == Owing to early availability of genome sequences for P. syringae pv. tomato strain DC3000, P. syringae pv. syringae strain B728a, and P. syringae pv. phaseolicola strain 1448A, together with the ability of selected strains to cause disease on well-characterized host plants such as Arabidopsis thaliana, Nicotiana benthamiana, and tomato, P. syringae has come to represent an important model system for experimental characterization of the molecular dynamics of plant-pathogen interactions. The P. syringae experimental system has been a source of pioneering evidence for the important role of pathogen gene products in suppressing plant defense. The nomenclature system developed for P. syringae effectors has been adopted by researchers characterizing effector repertoires in other bacteria, and methods used for bioinformatic effector identification have been adapted for other organisms. In addition, researchers working with P. syringae have played an integral role in the Plant-Associated Microbe Gene Ontology working group, aimed at developing gene ontology terms that capture biological processes occurring during the interactions between organisms, and using the terms for annotation of gene products.
== Materials used == Injectable fillers are composed of a wide range of natural and synthetic biomaterials, which can be categorized as resorbable or non-resorbable polymers. Injectable fillers are frequently formulated as hydrogels composed of hydrophilic polymer networks that can retain large amounts of water while maintaining structural integrity. Common materials include naturally derived polymers such as hyaluronic acid, gelatin, collagen, chitosan, alginate, and polysaccharides, as well as synthetic polymers like polyethylene glycol (PEG), poly(lactic acid), poly(methyl methacrylate), polyacrylamide, and dextran. These materials are often selected for their biocompatibility and structural similarity to the extracellular matrix, enabling integration with surrounding tissues. To enable in situ gelation, polymers are typically functionalized with reactive groups such as phenols, amines, or glutamine residues, allowing controlled crosslinking after injection. In advanced formulations, these hydrogel matrices may also serve as carriers for therapeutic fillers, including cells, proteins, or drugs, expanding their functionality beyond structural augmentation. Hyaluronic acid
Sources: en.wikipedia.org
This page is a list of Russian drugs, or drugs that were developed in Russia, the former Soviet Union, and/or post-Soviet countries. Many Russian drugs are indicated for enhancing physical, mental, and/or cognitive performance, including drugs described as nootropics or cognitive enhancers, drugs combatting fatigue, so-called adaptogens or actoprotectors, and others. There have been concerns about Russian drugs in the Western world owing to allegedly lower standards of medical evidence in Russia compared to the West, for instance in the case of the Russian COVID vaccine Sputnik V. Some Russian drugs have been attempted to be repurposed and developed by pharmaceutical companies for use in the West, such as phenylpiracetam (fonturacetam), (R)-phenylpiracetam (MRZ-9547), Noopept (omberacetam), and armesocarb (the active enantiomer of mesocarb).
To reduce poverty, encourage economic growth, and reduce congestion in Metro Manila, the Duterte administration launched its comprehensive infrastructure program, Build, Build, Build, on April 18, 2017. The program, which forms part of the administration's socioeconomic policy, aimed to usher in the country's "Golden Age of Infrastructure" by increasing the share of spending on public infrastructure in the country's gross domestic product (GDP) from 5.4 percent in 2017 to 7.4 percent in 2022. The administration, in 2017, shifted its infrastructure funding policy from public-private partnerships (PPPs) of previous administrations to government revenues and official development assistance (ODA), particularly from Japan and China, but has since October 2019 engaged with the private sector for additional funding. The administration revised its list of Infrastructure Flagship Projects (IFPs) under the Build, Build, Build program from 75 to 100 in November 2019, then to 104, and finally, to 112 in 2020, expanding its scope to include health, information and communications technology, and water infrastructure projects to support the country's economic growth and recovery from the COVID-19 pandemic. Some major projects include the Subic-Clark Railway, the North–South Commuter Railway from New Clark City to Calamba, Laguna, the Metro Manila Subway, the expansion of Clark International Airport, the Mindanao Railway (Tagum-Davao-Digos Segment), and the Luzon Spine Expressway Network.
== Licensing and partnerships == In July 2025, IGI entered a global licensing agreement with AbbVie for ISB 2001, a trispecific antibody in Phase 1 clinical trials for relapsed or refractory multiple myeloma. AbbVie obtained exclusive rights in North America, Europe, Japan, and Greater China, while Glenmark retained rights in India and other emerging markets. The deal included an upfront payment of $700 million, with potential milestones of up to $1.225 billion and tiered royalties on net sales. Glenmark has also in-licensed established oncology drugs. In September 2025 it licensed trastuzumab rezetecan from Hengrui Pharma for selected markets in a deal valued at up to $1.1 billion. In December 2025, Glenmark Specialty S.A. in-licensed aumolertinib from Hansoh Pharma for multiple regions. Aumolertinib had previously received approvals from the Medicines and Healthcare products Regulatory Agency and China's National Medical Products Administration for lung cancer treatment.
According to a recent patent application, yields of up to 95% are obtained with the same starting materials in toluene in the presence of potassium methoxide. It is subject to keto-enol tautomerism and exists predominantly enol when dissolved. Upon UV radiation, it may convert to keto form, while converting back to enol form after placing in dark.
Tyrosine sulfation is a posttranslational modification in which a tyrosine residue of a protein is sulfated by a tyrosylprotein sulfotransferase (TPST) typically in the Golgi apparatus. Secreted proteins and extracellular parts of membrane proteins that pass through the Golgi apparatus may be sulfated. Sulfation occurs in animals and plants but not in prokaryotes or in yeasts. Sulfation sites are tyrosine residues exposed on the surface of the protein typically surrounded by acidic residues. The function of sulfation remains uncertain.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.
No national medicines agency has approved melanotan-2 for clinical use. Afamelanotide, a related but distinct peptide, holds a marketing authorisation in the European Union for a rare photosensitivity disorder. Melanotan-2 itself is handled as a laboratory chemical.
Its broad activity across melanocortin receptors makes it a tool for probing pigmentation, appetite and vascular signalling. Early trials recorded skin darkening and other effects that were not the original focus of the work. Those observations generated hypotheses that later studies have examined.
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.